GlassScriptPhysician profile
John J Costello
NPI 1487650743
$4,552.70
in general payments reported to CMS, 2019-2025
27 companies · $934 in 2025
The $934 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $625 · 2021: $624 · 2022: $915 · 2023: $293 · 2024: $644 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,158.07 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Sight Sciences, INC. | $537.21 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $404.31 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $310.80 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $273.13 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $247.86 | 2021-2022 | |
| Oyster Point Pharma, INC. | $233.57 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $213.04 | 2025 | Envista Envy Iol, Miebo, Vyzulta |
| Dompe US, INC. | $146.80 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $142.76 | 2019-2022 | |
| Biotissue Holdings INC. | $136.36 | 2019-2024 | |
| Ocular Therapeutix, INC. | $123.60 | 2019-2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $84.13 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $71.75 | 2019-2021 | |
| Amgen INC. | $68.78 | 2024-2025 | Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68.23 | 2022-2024 | Durysta |
| Horizon Therapeutics Plc | $63.21 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.55 | 2020-2021 | |
| Teleflex LLC | $36.64 | 2024 | Arrow |
| Ivantis, INC | $35.01 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.61 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $28.34 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $26.19 | 2025 | Koselugo |
| Omeros Corporation | $20.35 | 2019 | |
| Eyepoint US, INC. | $17.83 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.65 | 2022 | |
| Abbott Laboratories | $13.92 | 2025 | Ensite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.